Loading clinical trials...
Loading clinical trials...
A Phase 2 Multicenter, Randomized, Double-blinded, Study to Describe the Safety, Efficacy, and Pharmacokinetics of Daptomycin 10 mg/kg/Day and Vancomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia
Conditions
Interventions
daptomycin
vancomycin
Locations
2
United States
East Carolina University
Greenville, North Carolina, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Start Date
September 17, 2008
Primary Completion Date
August 24, 2010
Completion Date
October 1, 2010
Last Updated
December 24, 2018
NCT06704048
NCT06269679
NCT06309680
NCT07313865
NCT04840225
NCT02128139
Lead Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions